Skip to menu Skip to content Skip to footer

2021

Journal Article

PET detectives: molecular imaging for phaeochromocytomas and paragangliomas in the genomics era

Ryder, Simon J., Love, Amanda J., Duncan, Emma L. and Pattison, David A. (2021). PET detectives: molecular imaging for phaeochromocytomas and paragangliomas in the genomics era. Clinical Endocrinology, 95 (1), 13-28. doi: 10.1111/cen.14375

PET detectives: molecular imaging for phaeochromocytomas and paragangliomas in the genomics era

2021

Journal Article

[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial

Hofman, Michael S., Emmett, Louise, Sandhu, Shahneen, Iravani, Amir, Joshua, Anthony M., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian D., Ng, Siobhan, Francis, Roslyn J., Gedye, Craig, Rutherford, Natalie K., Weickhardt, Andrew, Scott, Andrew M., Lee, Sze-Ting, Kwan, Edmond M., Azad, Arun A., Ramdave, Shakher, Redfern, Andrew D., Macdonald, William, Guminski, Alex, Hsiao, Edward, Chua, Wei, Lin, Peter, Zhang, Alison Y., McJannett, Margaret M., Stockler, Martin R., Violet, John A. ... TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (2021). [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. The Lancet, 397 (10276), 797-804. doi: 10.1016/S0140-6736(21)00237-3

[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial

2021

Journal Article

Clinical insignificance of [18F]PSMA-1007 avid non-specific bone lesions: a retrospective evaluation

Arnfield, Evyn G., Thomas, Paul A., Roberts, Matthew J., Pelecanos, Anita M., Ramsay, Stuart C., Lin, Charles Y., Latter, Melissa J., Garcia, Peter L. and Pattison, David A. (2021). Clinical insignificance of [18F]PSMA-1007 avid non-specific bone lesions: a retrospective evaluation. European Journal of Nuclear Medicine and Molecular Imaging, 48 (13), 4495-4507. doi: 10.1007/s00259-021-05456-3

Clinical insignificance of [18F]PSMA-1007 avid non-specific bone lesions: a retrospective evaluation

2019

Journal Article

Mitogen-activated protein kinase pathway inhibition for redifferentiation of radioiodine refractory differentiated thyroid cancer: an evolving protocol

Iravani, Amir, Solomon, Benjamin, Pattison, David A., Jackson, Price, Ravi Kumar, Aravind, Kong, Grace, Hofman, Michael S., Akhurst, Tim and Hicks, Rodney J. (2019). Mitogen-activated protein kinase pathway inhibition for redifferentiation of radioiodine refractory differentiated thyroid cancer: an evolving protocol. Thyroid, 29 (11), 1634-1645. doi: 10.1089/thy.2019.0143

Mitogen-activated protein kinase pathway inhibition for redifferentiation of radioiodine refractory differentiated thyroid cancer: an evolving protocol

2019

Journal Article

Personalised insulin calculator enables safe and effective correction of hyperglycaemia prior to FDG PET/CT

Pattison, David A., MacFarlane, Lisa L., Callahan, Jason, Kane, Emma L., Akhurst, Timothy and Hicks, Rodney J. (2019). Personalised insulin calculator enables safe and effective correction of hyperglycaemia prior to FDG PET/CT. EJNMMI Research, 9 (1) 15, 15. doi: 10.1186/s13550-019-0480-2

Personalised insulin calculator enables safe and effective correction of hyperglycaemia prior to FDG PET/CT

2017

Journal Article

18F-FDG–Avid Thyroid Incidentalomas: The Importance of Contextual Interpretation

Pattison, David A., Bozin, Michael, Gorelik, Alexandra, Hofman, Michael S., Hicks, Rodney J. and Skandarajah, Anita (2017). 18F-FDG–Avid Thyroid Incidentalomas: The Importance of Contextual Interpretation. Journal of Nuclear Medicine, 59 (5), 749-755. doi: 10.2967/jnumed.117.198085

18F-FDG–Avid Thyroid Incidentalomas: The Importance of Contextual Interpretation

2017

Journal Article

Molecular imaging in the investigation of hypoglycaemic syndromes and their management

Pattison, David A. and Hicks, Rodney J. (2017). Molecular imaging in the investigation of hypoglycaemic syndromes and their management. Endocrine-Related Cancer, 24 (6), R203-R221. doi: 10.1530/erc-17-0005

Molecular imaging in the investigation of hypoglycaemic syndromes and their management

2025

Journal Article

Phase Ib/IIa dose escalation and expansion study of [ <sup>212</sup> Pb]Pb-ADVC001 in metastatic castration-resistant prostate cancer: TheraPb–phase I/II study

Hansen, Aaron Richard, Pattison, David A., Ngai, Stanley, Karmann, Anna, Walker, Amanda J., Campbell, Louise, Brady, Jasmine, Katchel, Loren, Holmes, Ingrid, Rose, Stephen E., Baronet, Meghan C., Kryza, Thomas, Vito, Alyssa, Tieu, William, Kuan, Kevin, Griffiths, Matthew R., O’Mahoney, Eoin, Latter, Melissa, Gan, Chun Loo Loo and Wyld, David (2025). Phase Ib/IIa dose escalation and expansion study of [ 212 Pb]Pb-ADVC001 in metastatic castration-resistant prostate cancer: TheraPb–phase I/II study. Journal of Clinical Oncology, 43 (5_suppl). doi: 10.1200/jco.2025.43.5_suppl.tps275

Phase Ib/IIa dose escalation and expansion study of [ <sup>212</sup> Pb]Pb-ADVC001 in metastatic castration-resistant prostate cancer: TheraPb–phase I/II study

2025

Journal Article

Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial

Emmett, Louise, Subramaniam, Shalini, Crumbaker, Megan, Joshua, Anthony M, Sandhu, Shahneen, Nguyen, Andrew, Weickhardt, Andrew, Lee, Sze-Ting, Ng, Siobhan, Francis, Roslyn J, Goh, Jeffrey C, Pattison, David A, Tan, Thean Hsiang, Kirkwood, Ian D, Gedye, Craig, Rutherford, Natalie K, Kumar, Aravind S Ravi, Pook, David, Ramdave, Shakher, Nadebaum, David P, Voskoboynik, Mark, Redfern, Andrew D, Macdonald, William, Krieger, Laurence, Schembri, Geoff, Chua, Wei, Lin, Peter, Horvath, Lisa, Bastick, Patricia ... Bills, Madison (2025). Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial. The Lancet Oncology, 26 (3), 291-299. doi: 10.1016/s1470-2045(25)00009-9

Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial

2025

Journal Article

The global reading room: performing a ventilation-perfusion study in a patient with recent COVID-19

Grady, Erin, Pattison, David A., Redman, Stewart and Satoh, Yoko (2025). The global reading room: performing a ventilation-perfusion study in a patient with recent COVID-19. American Journal of Roentgenology, 224 (2), 1-2. doi: 10.2214/ajr.24.31348

The global reading room: performing a ventilation-perfusion study in a patient with recent COVID-19

2025

Journal Article

A Method for Validating PET and SPECT Cameras for Quantitative Clinical Imaging Trials Using Novel Radionuclides

Bailey, Dale L., Willowson, Kathy P., O’Keefe, Graeme, Goodman, Steven, Patford, Shaun, McGill, George, Pattison, David A. and Scott, Andrew M. (2025). A Method for Validating PET and SPECT Cameras for Quantitative Clinical Imaging Trials Using Novel Radionuclides. Journal of Nuclear Medicine, 66 (2), 315-322. doi: 10.2967/jnumed.124.268578

A Method for Validating PET and SPECT Cameras for Quantitative Clinical Imaging Trials Using Novel Radionuclides

2024

Journal Article

Successful Localization of Recurrent MEN-1-Associated Hyperparathyroidism With 18F-Fluorocholine PET/CT

Wootton, Elizabeth, Wong, Clement, Love, Amanda and Pattison, David A (2024). Successful Localization of Recurrent MEN-1-Associated Hyperparathyroidism With 18F-Fluorocholine PET/CT. JCEM Case Reports, 2 (12), luae222. doi: 10.1210/jcemcr/luae222

Successful Localization of Recurrent MEN-1-Associated Hyperparathyroidism With 18F-Fluorocholine PET/CT

2024

Journal Article

Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study

Azad, Arun A, Bressel, Mathias, Tan, Hsiang, Voskoboynik, Mark, Suder, Aneta, Weickhardt, Andrew J, Guminski, Alexander, Francis, Roslyn J, Saghebi, Javad, Dhiantravan, Nattakorn, Joshua, Anthony M, Emmett, Louise, Horvath, Lisa, Murphy, Declan G, Hsiao, Edward, Balakrishnar, Bavanthi, Lin, Peter, Redfern, Andrew, Macdonald, William, Ng, Siobhan, Lee, Sze-Ting, Pattison, David A, Nadebaum, David, Kirkwood, Ian D, Hofman, Michael S, Akhurst, T, Alipour, R, Au, L, Banks, P ... Ratnayake, L (2024). Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study. The Lancet Oncology, 25 (10), 1267-1276. doi: 10.1016/s1470-2045(24)00440-6

Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study

2024

Journal Article

The role of prostate-specific membrane antigen positron emission tomography/computed tomography in primary staging of selected renal tumours: initial experience in a multicentre cohort

Tariq, Arsalan, Pearce, Adam, Rhee, Handoo, Kyle, Samuel, Raveenthiran, Sheliyan, Pelecanos, Anita, Gan, Chun Loo, Goh, Jeffrey C., Wong, David, McBean, Rhiannon, Marsh, Phillip, Goodman, Steven, Dunglison, Nigel, Esler, Rachel, Navaratnam, Anojan, Yaxley, John W., Thomas, Paul, Pattison, David A. and Roberts, Matthew J. (2024). The role of prostate-specific membrane antigen positron emission tomography/computed tomography in primary staging of selected renal tumours: initial experience in a multicentre cohort. European Urology Focus, 10 (5), 770-778. doi: 10.1016/j.euf.2023.12.004

The role of prostate-specific membrane antigen positron emission tomography/computed tomography in primary staging of selected renal tumours: initial experience in a multicentre cohort

2024

Conference Publication

A randomised phase II study of sequential 177Lu-PSMA-617 and docetaxel (D) versus docetaxel in metastatic hormone-sensitive prostate cancer (mHSPC)

Azad, A.A., Bressel, M., Tan, H., Voskoboynik, M., Suder, A., Weickhardt, A.J., Guminski, A., Francis, R.J., Saghebi, J., Dhiantravan, N., Joshua, A., Emmett, L., Murphy, D., Hsiao, E., Lee, S.T., Pattison, D.A., Nadebaum, D., Kirkwood, I.D. and Hofman, M.S. (2024). A randomised phase II study of sequential 177Lu-PSMA-617 and docetaxel (D) versus docetaxel in metastatic hormone-sensitive prostate cancer (mHSPC). ESMO Congress 2024, Barcelona, Spain, 13-17 September 2024. Amsterdam, Netherlands: Elsevier. doi: 10.1016/j.annonc.2024.08.2309

A randomised phase II study of sequential 177Lu-PSMA-617 and docetaxel (D) versus docetaxel in metastatic hormone-sensitive prostate cancer (mHSPC)

2024

Journal Article

Clinical trial protocol for PRIMARY2: a multicentre, phase 3, randomised controlled trial investigating the additive diagnostic value of [68Ga]Ga-PSMA-11 positron emission tomography/computed tomography in men with negative or equivocal multiparametric magnetic resonance imaging for the diagnosis of clinically significant prostate cancer

Buteau, James P., Moon, Daniel, Fahey, Michael T., Roberts, Matthew J., Thompson, James, Murphy, Declan G., Papa, Nathan, Mitchell, Catherine, De Abreu Lourenco, Richard, Dhillon, Haryana M., Kasivisvanathan, Veeru, Francis, Roslyn J., Stricker, Phillip, Agrawal, Shihka, O'Brien, Jonathan, McVey, Aoife, Sharma, Gaurav, Levy, Sidney, Ayati, Narjess, Nguyen, Andrew, Lee, Su-Faye, Pattison, David A., Sivaratnam, Dinesh, Frydenberg, Mark, Du, Yang, Titus, Jehan, Lee, Sze-Ting, Ischia, Joseph, Jack, Greg ... Emmett, Louise (2024). Clinical trial protocol for PRIMARY2: a multicentre, phase 3, randomised controlled trial investigating the additive diagnostic value of [68Ga]Ga-PSMA-11 positron emission tomography/computed tomography in men with negative or equivocal multiparametric magnetic resonance imaging for the diagnosis of clinically significant prostate cancer. European Urology Oncology, 7 (3), 544-552. doi: 10.1016/j.euo.2023.11.008

Clinical trial protocol for PRIMARY2: a multicentre, phase 3, randomised controlled trial investigating the additive diagnostic value of [68Ga]Ga-PSMA-11 positron emission tomography/computed tomography in men with negative or equivocal multiparametric magnetic resonance imaging for the diagnosis of clinically significant prostate cancer

2024

Journal Article

[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial

Emmett, Louise, Subramaniam, Shalini, Crumbaker, Megan, Nguyen, Andrew, Joshua, Anthony M., Weickhardt, Andrew, Lee, Sze-Ting, Ng, Siobhan, Francis, Roslyn J., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian D., Gedye, Craig, Rutherford, Natalie K., Sandhu, Shahneen, Kumar, Aravind Ravi, Pook, David, Ramdave, Shakher, Nadebaum, David P., Voskoboynik, Mark, Redfern, Andrew D., Macdonald, William, Krieger, Laurence, Schembri, Geoff, Chua, Wei, Lin, Peter, Horvath, Lisa, Bastick, Patricia ... Davis, Ian D. (2024). [177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial. The Lancet Oncology, 25 (5), 563-571. doi: 10.1016/s1470-2045(24)00135-9

[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial

2024

Book Chapter

Nontoxic diffuse goiter, nodular thyroid disorders, and thyroid malignancies

Alexander, Erik K., Haymart, Megan R., Pattison, David A., Wirth, Lori J. and Zeiger, Martha A. (2024). Nontoxic diffuse goiter, nodular thyroid disorders, and thyroid malignancies. Williams textbook of endocrinology. (pp. 430.e14-470.e14) edited by Shlomo Melmed, Richard J. Auchus, Allison B. Goldfine, Clifford J. Rosen and Peter A. Kopp. Amsterdam, Netherlands: Elsevier. doi: 10.1016/B978-0-323-93230-1.00012-9

Nontoxic diffuse goiter, nodular thyroid disorders, and thyroid malignancies

2024

Journal Article

First-in-human212Pb-PSMA–targeted α-therapy SPECT/CT imaging in a patient with metastatic castration-resistant prostate cancer

Griffiths, Matthew R., Pattison, David A., Latter, Melissa, Kuan, Kevin, Taylor, Stephen, Tieu, William, Kryza, Thomas, Meyrick, Danielle, Lee, Boon Quan, Hansen, Aaron, Rose, Stephen E. and Puttick, Simon G. (2024). First-in-human212Pb-PSMA–targeted α-therapy SPECT/CT imaging in a patient with metastatic castration-resistant prostate cancer. Journal of Nuclear Medicine, 65 (4), 664-664. doi: 10.2967/jnumed.123.267189

First-in-human212Pb-PSMA–targeted α-therapy SPECT/CT imaging in a patient with metastatic castration-resistant prostate cancer

2024

Journal Article

Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial

Hofman, Michael S., Emmett, Louise, Sandhu, Shahneen, Iravani, Amir, Buteau, James P., Joshua, Anthony M., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian D., Ng, Siobhan, Francis, Roslyn J., Gedye, Craig, Rutherford, Natalie K., Weickhardt, Andrew, Scott, Andrew M., Lee, Sze-Ting, Kwan, Edmond M., Azad, Arun A., Ramdave, Shakher, Redfern, Andrew D., Macdonald, William, Guminski, Alex, Hsiao, Edward, Chua, Wei, Lin, Peter, Zhang, Alison Yan, Stockler, Martin R., Williams, Scott G. ... Yip, Sonia (2024). Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial. The Lancet Oncology, 25 (1), 99-107. doi: 10.1016/s1470-2045(23)00529-6

Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial